If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Product Launch » Market Entry and Oncology
Download FREE Excerpt
21 Info Graphics
29 Data Graphics
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
New oncology products are constantly entering the biopharmaceutical marketplace; some therapies are immediate successes while others flounder for months. While there are a myriad of factors that go into preparing a new oncology pharmaceutical product for market entry, one of the key selling points is a product's characteristics.
Thus, how an oncology product differentiates itself from existing therapies, how it is priced in the market and its benefits - ease of use, fewer side effects, etc. - are all important factors that shape a new oncology product's market entry.
Best Practices, LLC conducted this study to highlight the effectiveness of different tactics regarding differentiation, pricing and product benefits. The study also reviews issues surrounding a product's safety and efficacy profile to determine how much more effective or safe a new oncology product needs to be to have a successful market entry. Launch leaders can use this research as part of building their market entry strategy for new oncology products.
This study includes two segments: one representing the entire benchmark class and one representing the oncology therapeutic area.
The research employed a data gathering approach that gleaned quantitative data from 44 executives and managers from 38 leading companies in pharmaceutical, biotechnology and medical device industries. In addition, six executives participated in in-depth interviews.